86008
document
Hypotensive effects and influence on serum lipids of SQ29,852 , a new angiotensin converting enzyme inhibitor , in patients with essential hypertension : a comparison with atenolol . The effects of SQ29,852 ( n = 24 ) , a new angiotensin converting enzyme inhibitor , and atenolol ( n = 22 ) , monotherapies were compared in 46 patients with mild to moderate essential hypertension . Both SQ29,852 ( mean dose 15.0 +/- 5.1 mg/day ) and atenolol ( mean dose 37.5 +/- 18.5 mg/day ) significantly decreased both systolic and diastolic blood pressures . There were no significant changes in serum lipids , apolipoproteins , lipoproteins or atherosclerotic indices after both SQ29,852 and atenolol . There were also no significant inter-group differences . There were no serious side effects or abnormal laboratory tests in both treatment groups . It is concluded that SQ29,852 is an effective antihypertensive drug without adverse effect on lipid metabolism .
86009
Intervention_Pharmacological
SQ29,852 , a new angiotensin converting enzyme inhibitor
86010
Intervention_Pharmacological
atenolol
86011
Intervention_Pharmacological
SQ29,852
86012
Intervention_Pharmacological
angiotensin converting enzyme inhibitor
86013
Intervention_Pharmacological
atenolol
86014
Intervention_Pharmacological
SQ29,852
86015
Intervention_Pharmacological
atenolol
86016
Intervention_Pharmacological
SQ29,852
86017
Intervention_Pharmacological
atenolol
86018
Intervention_Pharmacological
SQ29,852
86019
Outcome_Physical
serum lipids
86020
Outcome_Physical
systolic and diastolic blood pressures
86021
Outcome_Physical
serum lipids , apolipoproteins , lipoproteins or atherosclerotic indices
86022
Outcome_Adverse-effects
serious side effects or abnormal laboratory tests
86023
Outcome_Adverse-effects
adverse effect
86024
Participant_Condition
patients with essential hypertension :